PharmiWeb.com - Global Pharma News & Resources

Clinical research - Press Releases

Date Title Company
06-Nov-2024 Cambridge Cognition spin-out, Monument Therapeutics, receives £1.0 million for schizophrenia clinical development Cambridge Cognition
05-Nov-2024 Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development Xeltis
04-Nov-2024 Oak Hill Bio and Chiesi Group Announce First European Patient Enrolled in the Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants Chiesi
01-Nov-2024 Overcollection of data adds months to clinical trials and reduces ROI, finds new Phesi analysis Phesi
01-Nov-2024 Cambridge Cognition announces new data demonstrating effectiveness of proprietary AQUA Cambridge Cognition
01-Nov-2024 PureTech to Present at Two Upcoming Investor Conferences PureTech Health plc
01-Nov-2024 Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study Tiziana Life Sciences
29-Oct-2024 Dr. Falk Pharma acquires spinout Kynos Therapeutics to develop novel KMO inhibitors for acute pancreatitis Edinburgh Innovations
29-Oct-2024 Medidata and Cogstate Strike Strategic Partnership Transforming Clinical Trials in Neurology with Clinical Outcome Assessment (eCOA) and Clinician Solutions Powered by AI and Advanced Analytics Medidata
29-Oct-2024 Almirall launches the campaign “Me & My Inner Circle” to acknowledge the vital role of friends and family for people living with psoriasis Almirall
29-Oct-2024 Alira Health Releases Global Report on Trends and Competitive Dynamics in the Biosimilar Market Alira Health
29-Oct-2024 TREMFYA® (Guselkumab) is the first IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn’s disease JOHNSON & JOHNSON
28-Oct-2024 Almirall´s 2024 Immunoskin conference hosts leading experts in inflammatory skin conditions to advance science and treatment options Almirall
28-Oct-2024 UPM Biomedicals launches FibGel™ the world’s first injectable nanocellulose hydrogel for medical devices UPM Biomedicals
28-Oct-2024 Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis AstraZeneca
28-Oct-2024 Innovative Trials named a top UK women-powered company in clinical research Innovative Trials
28-Oct-2024 Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2 Bi-Functional Antibody Planned to Enter the Clinic in 2025 Ottimo Pharma
28-Oct-2024 ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement ProQR
28-Oct-2024 Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance Sanofi
28-Oct-2024 Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule Orion Corporation